SynthesisPloS one2017
Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Epigenetic silencing of the tumor suppressor TIMP-3 gene in upstream CpG islands in thyroid neoplasms: a cross-sectional study with systematic review.Molecular biology reports · 2025Pooled it
- Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.Endocrine · 2020Pooled it
- Pooled it
- Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020.Journal of diabetes and metabolic disorders · 2024Review
- CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.International journal of molecular sciences · 2023Review
- Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma.Cancer cell international · 2022Article
- BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture.Cancer cell international · 2022Article
- The Epigenetic Modification ofIranian journal of public health · 2022Article
- Epigenetic modification and BRAF gene mutation in thyroid carcinoma.Cancer cell international · 2021Review
- Promoter Methylation of Tumor Suppressors in Thyroid Carcinoma: A Systematic Review.Iranian journal of public health · 2021Review
- DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer development and progression.Annals of translational medicine · 2021Article
- Endocrinology and Metabolism Research Institute from inception to maturity: an overview of 25-year activity.Journal of diabetes and metabolic disorders · 2020Article
- Article
- Voltammetric immunosensor for E-cadherin promoter DNA methylation using a FeMikrochimica acta · 2019Article
- Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.International journal of molecular and cellular medicine · 2019Review
- Oncometabolites as biomarkers in thyroid cancer: a systematic review.Cancer management and research · 2019Review
- Personalized treatment options for thyroid cancer: current perspectives.Pharmacogenomics and personalized medicine · 2019Review
- Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma.Iranian journal of pathology · 2019Article
- An integrated methylation and gene expression microarray analysis reveals significant prognostic biomarkers in oral squamous cell carcinoma.Oncology reports · 2018Article
- Liquid Biopsy in Thyroid Cancer: New Insight.International journal of hematology-oncology and stem cell research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promoter methylation in a number of tumor-suppressor genes (TSGs) can play crucial roles in the development of thyroid carcinogenesis. The focus of the current meta-analysis was to determine the impact of promoter methylation of eight selected candidate TSGs on thyroid cancer and to identify the most important molecules in this carcinogenesis pathway. A comprehensive search was performed using Pub Med, Scopus, and ISI Web of Knowledge databases, and eligible studies were included. The methodological quality of the included studies was evaluated according to the Newcastle Ottawa scale table and pooled odds ratios (ORs); 95% confidence intervals (CIs) were used to estimate the strength of the associations with Stata 12.0 software. Egger's and Begg's tests were applied to detect publication bias, in addition to the "Metatrim" method. A total of 55 articles were selected, and 135 genes with altered promoter methylation were found. Finally, we included eight TSGs that were found in more than four studies (RASSF1, TSHR, PTEN, SLC5A, DAPK, P16, RARβ2, and CDH1). The order of the pooled ORs for these eight TSGs from more to less significant was CDH1 (OR = 6.73), SLC5 (OR = 6.15), RASSF1 (OR = 4.16), PTEN (OR = 3.61), DAPK (OR = 3.51), P16 (OR = 3.31), TSHR (OR = 2.93), and RARβ2 (OR = 1.50). Analyses of publication bias and sensitivity confirmed that there was very little bias. Thus, our findings showed that CDH1 and SCL5A8 genes were associated with the risk of thyroid tumor genesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.